These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33687857)

  • 61. [Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
    Hosaka T; Suzuki F; Kumada H
    Nihon Shokakibyo Gakkai Zasshi; 2011 Feb; 108(2):210-4. PubMed ID: 21307624
    [No Abstract]   [Full Text] [Related]  

  • 62. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Suppressing hepatitis B without resistance--so far, so good.
    Mailliard ME; Gollan JL
    N Engl J Med; 2003 Feb; 348(9):848-50. PubMed ID: 12606741
    [No Abstract]   [Full Text] [Related]  

  • 64. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatitis B: explosion of new knowledge.
    Keeffe EB
    Gastroenterology; 2007 Nov; 133(5):1718-21. PubMed ID: 17983813
    [No Abstract]   [Full Text] [Related]  

  • 66. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 67. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
    Murata K; Tsukuda S; Suizu F; Kimura A; Sugiyama M; Watashi K; Noguchi M; Mizokami M
    Hepatology; 2020 May; 71(5):1533-1545. PubMed ID: 31529730
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
    [TBL] [Abstract][Full Text] [Related]  

  • 71. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
    Yang S; Xing H; Wang Q; Wang X; Liu S; Cheng J
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():24. PubMed ID: 27079793
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy].
    Orito E
    Nihon Shokakibyo Gakkai Zasshi; 2007 Oct; 104(10):1459-64. PubMed ID: 17917393
    [No Abstract]   [Full Text] [Related]  

  • 76. New perspectives in the therapy of chronic hepatitis B.
    Lampertico P; Liaw YF
    Gut; 2012 May; 61 Suppl 1():i18-24. PubMed ID: 22504916
    [No Abstract]   [Full Text] [Related]  

  • 77. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection.
    Mak LY; Seto WK; Lai CL; Yuen MF
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):101-106. PubMed ID: 29237296
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
    Caviglia GP; Olivero A; Ngatchou D; Saracco GM; Smedile A
    Minerva Gastroenterol Dietol; 2019 Mar; 65(1):77-78. PubMed ID: 30037184
    [No Abstract]   [Full Text] [Related]  

  • 80. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
    Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV
    Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.